2. Search Result
Search Result
Results for "

Skin cancer models

" in MedChemExpress (MCE) Product Catalog:

7

Inhibitors & Agonists

1

Peptides

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2877
    Annonacin
    1 Publications Verification

    		 Potassium Channel Sodium Channel Na+/K+ ATPase Calcium Channel Apoptosis Neurological Disease Cancer
    Annonacin is an acetylgenin that is toxic by inhibiting the pathway of the mitochondrial complex. Annonacin increases tau phosphorylation in R406W +/+ mice. Annonacin acts as an inhibitor of the sodium/potassium and sarcoplasmic reticulum (SERCA) ATPase pumps. Annonacin has significant killing effect on ovarian cancer cell, cervical cancer cell, breast cancer cell, bladder cancer cell and skin cancer cell. Annonacin induces apoptosis through Bax and Caspase-3-related pathways .
    Annonacin
  • HY-176798
    NCI-006

    		Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis Cancer
    NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC50 = 0.06 μM; LDHB IC50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .
    NCI-006
  • HY-141439
    TBE 31

    		Keap1-Nrf2 Quinone Reductase Glutathione S-transferase Apoptosis TNF Receptor Inflammation/Immunology Cancer
    TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1. TBE 31 binds to cysteine residues of Keap1, inhibits ubiquitination and degradation of Nrf2, thereby activating the expression of ARE-dependent genes. TBE 31 induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated genes related to antioxidation and lipid metabolism. TBE 31 inhibits pro-inflammatory responses, formation of AFB1-DNA adducts, endoplasmic reticulum stress, cell apoptosis (apoptosis), hepatic fibrosis, oxidative stress, and the expression of ChREBP. TBE 31 reduces the number of tumors in a mouse model of ultraviolet-induced skin carcinogenesis. TBE 31 enhances nerve growth factor-induced neurite outgrowth. TBE 31 attenuates LPS-induced serum TNF-α levels and immobility time in mice. TBE 31 can be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis .
    TBE 31
  • HY-Y1356
    2,4-Dimethoxybenzaldehyde

    		Biochemical Assay Reagents Cancer
    2,4-Dimethoxybenzaldehyde is a tumor initiator with genotoxic property. 2,4-Dimethoxybenzaldehyde can induce benign papilloma development and converse to squamous cell carcinoma in the skin of susceptible mouse models. 2,4-Dimethoxybenzaldehyde can be used for skin cancer research .
    2,4-Dimethoxybenzaldehyde
  • HY-P11417
    Epidermal mitosis inhibiting pentapeptide

    		DNA/RNA Synthesis Cancer
    Epidermal mitosis inhibiting pentapeptide is a five-peptide that acts as a physiological inhibitor of epidermal cell proliferation. This pentapeptide can significantly reduce the DNA synthesis rate and mitotic rate of epidermal keratinocytes. Epidermal mitosis inhibiting pentapeptide moderately enhances the occurrence of skin tumors in skin cancer models, but also shows a higher tendency to promote the regression of already formed tumors. Epidermal mitosis inhibiting pentapeptide can be hydrolyzed by angiotensin-converting enzyme (ACE). Epidermal mitosis inhibiting pentapeptide can be used in cancer process research .
    Epidermal mitosis inhibiting pentapeptide
  • HY-168729
    Antibacterial agent 256

    		Bacterial Infection
    Antibacterial agent 256 (Compound C09) is an inhibitor for type I signal peptidase (SPase I). Antibacterial agent 256 inhibits gram-positive bacteria, that inhibits S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1 and S. suis P1/7, with MIC of 1-16 μg/mL. Antibacterial agent 256 exhibits cytotoxicity in cancer cell HEp-2 and Caco-2 with CC50 of 14.65 μg/mL and 21.93 μg/mL. Antibacterial agent 256 exhibits a hemolytic activity on mouse RBCs, with an HC50 of 13.29 μg/mL. Antibacterial agent 256 ameliorates the MRSA skin infection in mouse model .
    Antibacterial agent 256
  • HY-N18070
    12-Deoxyphorbol-13-isobutyrate-20-acetate

    		Drug Derivative PKC Fungal Cardiovascular Disease Infection Inflammation/Immunology Cancer
    12-Deoxyphorbol-13-isobutyrate-20-acetate is a 12-deoxy-phorbol diterpene ester. 12-Deoxyphorbol-13-isobutyrate-20-acetate is a protein kinase C (PKC) agonist that activates protein kinase C to phosphorylate troponin I and troponin T. 12-Deoxyphorbol-13-isobutyrate-20-acetate induces skin irritation and necrosis in mice without cocarcinogenic activity. 12-Deoxyphorbol-13-isobutyrate-20-acetate inhibits Aspergillus carbonarius growth. 12-Deoxyphorbol-13-isobutyrate-20-acetate supports research on heart failure, cardiomyopathies and fungal infection .
    12-Deoxyphorbol-13-isobutyrate-20-acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: